Korean drugmakers are eyeing opportunities to enlarge their overseas market shares at an upcoming event in the U.S. and U.K. next month.
The companies plan to unveil their research outcomes at the 2018 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Ill., from April 14-18.
Founded in 1907 as the first and the largest association of cancer researchers, the AACR holds annual meetings to introduce latest trends in cancer-related therapies. More than 20,000 participants from 70 countries attend the event every year.
At the AACR annual meeting, participants focus more on sharing study results than exchanging business opportunities for licensing-in or licensing-out deals.
However, local drugmakers have attended the annual events over the recent years to increase the chance of overseas deals during meetings with international researchers, while explaining about the companies’ major pipelines and key research areas.
Domestic companies participating in the AACR 2018 meeting include Hanmi Pharmaceutical, Yuhan Corp., Boryung Pharmaceutical, Genexine, NeoImmuneTech, and HLB. They will introduce their study results in poster presentations.
Hanmi Pharm is to introduce two drug candidates -- HM43239 and HM81422 -- on April 15 and 17, respectively. HM43239 is an FLT3 (fms-like tyrosine kinase 3) inhibitor-based investigational treatment for acute myeloid leukemia. The company hopes that it can help patients overcome resistance to existing FLT3-based therapies. HM81422 is an FGFR4 (fibroblast growth factor receptor 4) inhibitor-based targeted anti-cancer treatment, with expected efficacy to treat liver cancer.
On April 17, Yuhan will unveil the result of clinical trials on YH25448, an experimental drug for third-generation non-small cell lung cancer. The company earlier said it planned to finish the phase-1 trials and advance the closing of the phase-2 trials in Korea.
Boryung Pharm is to attend the poster sessions on April 15-16 to introduce BR101801, a candidate drug substance for non-Hodgkin's lymphoma.
Genexine and NeoImmuneTech will jointly introduce the immunotherapeutic agent candidate HyLeukin at the U.S. event. Genexine plans to introduce the effectiveness of HyLeukin as a single and combination therapy. HyLeukin is a new drug pipeline that combined optimized interleukin-7 (IL-7) with hyFc, an original technology owned by Genexine. The drug candidate can be applied to various diseases including cancer, infectious diseases, and lymphopenia, according to the company.
HLB will be attending the AACR meeting via its subsidiary LSKB. LSKB will explain about a study on a novel drug candidate for lung cancer which can act as an assisting agent for apatinib, a selective VEGFT-2 inhibitor.
“Experts exchange the latest knowledge, drug information, study outcomes and their experiences at the AACR meeting,” said an official at a pharmaceutical company, which is to attend the event. “ Possibilities are open for licensing-in and licensing-out deals through meetings with researchers. The event is coveted by oncolytic agent developers because they can introduce their study results to the world.”
Sillajen, which was expected to participate in the AACR event, is heading to the U.K. to join the International Oncolytic Virus Conference 2018, to be held in London from April 9-12.
The company is to introduce its pipelines and reveal results of the trials on Pexa-Vec, genetically-engineered oncolytic virus.
<© Korea Biomedical Review, All rights reserved.>